Pasithea Therapeutics Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp. on September 16, 2025. The filing primarily addresses clinical trial progress for the Company's lead candidate, PAS-004, specifically within the context of neurofibromatosis type 1 (NF1).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a clinical-stage biopharmaceutical company reporting a specific operational event, this 8-K does not contain a financial statement or quarterly results.
Material Changes and Operational Updates
- International Expansion: Activated two clinical trial sites in South Korea for the Phase 1/1b NF1 Trial: Asan Medical Centre and Severance Hospital Yonsei University Health System.
- Patient Dosing: Confirmed that the first patient in South Korea has been dosed.
- Cohort Progression: The trial is currently enrolling patients in Cohort 2 (8mg tablet). This follows a recommendation by the external Safety Review Committee to proceed past Cohort 1 (4mg tablet) without modification.
- Data Timeline: Initial interim clinical data from the first two cohorts of the NF1 Trial is expected in the first quarter of 2026.
Outlook, Risks, and Management Commentary
Management highlighted the successful expansion of the NF1 Trial into South Korea and the positive safety review allowing dose escalation. The filing includes standard forward-looking statements regarding the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of PAS-004.
Risks and Contingencies: The Company notes that actual results could differ materially from expectations due to risks including negative or ambiguous clinical trial results, failure to reach statistical significance for regulatory approval, and other factors detailed in recent 10-K and 10-Q filings. The Company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the enrollment status and recruitment rates at the newly activated South Korean sites.
- Monitor the timeline for the release of interim clinical data expected in Q1 2026.
- Review the most recent Form 10-K and 10-Q for updated cash runway and liquidity positions, as this 8-K does not contain financial data.
- Confirm the composition and findings of the external Safety Review Committee regarding the transition from Cohort 1 to Cohort 2.